-
1
-
-
85013312416
-
Tumor angiogenesis: Therapeutic implications
-
Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182-1186, 1971.
-
(1971)
N Engl J Med
, vol.285
, pp. 1182-1186
-
-
Folkman, J.1
-
2
-
-
15544381413
-
Receptor tyrosine kinases and anticancer therapy
-
Medinger M and Drevs J: Receptor tyrosine kinases and anticancer therapy. Curr Pharm Des 11: 1139-1149, 2005.
-
(2005)
Curr Pharm des
, vol.11
, pp. 1139-1149
-
-
Medinger, M.1
Drevs, J.2
-
3
-
-
0028929803
-
Angiogenesis in cancer, vascular, rheumatoid and other disease
-
Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27-31, 1995.
-
(1995)
Nat Med
, vol.1
, pp. 27-31
-
-
Folkman, J.1
-
4
-
-
0034282515
-
Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model
-
Drevs J, Hofmann I, Hugenschmidt H, Wittig C, Madjar H, Muller M, Wood J, Martiny-Baron G, Unger C and Marme D: Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. Cancer Res 60: 4819-4824, 2000.
-
(2000)
Cancer Res
, vol.60
, pp. 4819-4824
-
-
Drevs, J.1
Hofmann, I.2
Hugenschmidt, H.3
Wittig, C.4
Madjar, H.5
Muller, M.6
Wood, J.7
Martiny-Baron, G.8
Unger, C.9
Marme, D.10
-
5
-
-
20044375036
-
The VEGF receptor tyrosine kinase inhibitor, ZD6474, inhibits angiogenesis and affects microvascular architecture within an orthotopically implanted renal cell carcinoma
-
Drevs J, Konerding MA, Wolloscheck T, Wedge SR, Ryan AJ, Ogilvie DJ and Esser N: The VEGF receptor tyrosine kinase inhibitor, ZD6474, inhibits angiogenesis and affects microvascular architecture within an orthotopically implanted renal cell carcinoma. Angiogenesis 7: 347-354, 2004.
-
(2004)
Angiogenesis
, vol.7
, pp. 347-354
-
-
Drevs, J.1
Konerding, M.A.2
Wolloscheck, T.3
Wedge, S.R.4
Ryan, A.J.5
Ogilvie, D.J.6
Esser, N.7
-
6
-
-
0027197245
-
Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo
-
Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS and Ferrara N: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 362: 841-844, 1993.
-
(1993)
Nature
, vol.362
, pp. 841-844
-
-
Kim, K.J.1
Li, B.2
Winer, J.3
Armanini, M.4
Gillett, N.5
Phillips, H.S.6
Ferrara, N.7
-
7
-
-
75149149393
-
Antitumor and antiangiogenic activity of cediranib in a preclinical model of renal cell carcinoma
-
Medinger M, Esser N, Zirrgiebel U, Ryan A, Jürgensmeier JM and Drevs J: Antitumor and antiangiogenic activity of cediranib in a preclinical model of renal cell carcinoma. Anticancer Res 29: 5065-5076, 2009.
-
(2009)
Anticancer Res
, vol.29
, pp. 5065-5076
-
-
Medinger, M.1
Esser, N.2
Zirrgiebel, U.3
Ryan, A.4
Jürgensmeier, J.M.5
Drevs, J.6
-
8
-
-
33846148701
-
Target Study Group: Sorafenib in advanced clear-cell renal-cell carcinoma
-
Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R and Bukowski RM: Target Study Group: sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356: 125-134, 2007.
-
(2007)
N Engl J Med
, vol.356
, pp. 125-134
-
-
Escudier, B.1
Eisen, T.2
Stadler, W.M.3
Szczylik, C.4
Oudard, S.5
Siebels, M.6
Negrier, S.7
Chevreau, C.8
Solska, E.9
Desai, A.A.10
Rolland, F.11
Demkow, T.12
Hutson, T.E.13
Gore, M.14
Freeman, S.15
Schwartz, B.16
Shan, M.17
Simantov, R.18
Bukowski, R.M.19
-
9
-
-
33846181370
-
Sunitinib versus interferon alpha in metastatic renal-cell carcinoma
-
Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM and Figlin RA: Sunitinib versus interferon alpha in metastatic renal-cell carcinoma. N Engl J Med 356: 115-124, 2007.
-
(2007)
N Engl J Med
, vol.356
, pp. 115-124
-
-
Motzer, R.J.1
Hutson, T.E.2
Tomczak, P.3
Michaelson, M.D.4
Bukowski, R.M.5
Rixe, O.6
Oudard, S.7
Negrier, S.8
Szczylik, C.9
Kim, S.T.10
Chen, I.11
Bycott, P.W.12
Baum, C.M.13
Figlin, R.A.14
-
10
-
-
2542561964
-
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
-
Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R and Kabbinavar F: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342, 2004.
-
(2004)
N Engl J Med
, vol.350
, pp. 2335-2342
-
-
Hurwitz, H.1
Fehrenbacher, L.2
Novotny, W.3
Cartwright, T.4
Hainsworth, J.5
Heim, W.6
Berlin, J.7
Baron, A.8
Griffing, S.9
Holmgren, E.10
Ferrara, N.11
Fyfe, G.12
Rogers, B.13
Ross, R.14
Kabbinavar, F.15
-
11
-
-
0842311621
-
Vascular targeting agents as cancer therapeutics
-
Thorpe PE: Vascular targeting agents as cancer therapeutics. Clin Cancer Res 10: 415-427, 2004.
-
(2004)
Clin Cancer Res
, vol.10
, pp. 415-427
-
-
Thorpe, P.E.1
-
13
-
-
0037115398
-
ZD6126: A novel vascular-targeting agent that causes selective destruction of tumor vasculature
-
Davis PD, Dougherty GJ, Blakey DC, Galbraith SM, Tozer GM, Holder AL, Naylor MA, Nolan J, Stratford MR, Chaplin DJ and Hill SA: ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature. Cancer Res 62: 7247-7253, 2002.
-
(2002)
Cancer Res
, vol.62
, pp. 7247-7253
-
-
Davis, P.D.1
Dougherty, G.J.2
Blakey, D.C.3
Galbraith, S.M.4
Tozer, G.M.5
Holder, A.L.6
Naylor, M.A.7
Nolan, J.8
Stratford, M.R.9
Chaplin, D.J.10
Hill, S.A.11
-
14
-
-
0036278972
-
Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models
-
Blakey DC, Westwood FR, Walker M, Hughes GD, Davis PD, Ashton SE and Ryan AJ: Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clin Cancer Res 8: 1974-1983, 2002.
-
(2002)
Clin Cancer Res
, vol.8
, pp. 1974-1983
-
-
Blakey, D.C.1
Westwood, F.R.2
Walker, M.3
Hughes, G.D.4
Davis, P.D.5
Ashton, S.E.6
Ryan, A.J.7
-
15
-
-
0036569804
-
Enhancement of radiation therapy by the novel vascular targeting agent ZD6126
-
Siemann DW and Rojiani AM: Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys 53: 164-171, 2002.
-
(2002)
Int J Radiat Oncol Biol Phys
, vol.53
, pp. 164-171
-
-
Siemann, D.W.1
Rojiani, A.M.2
-
16
-
-
2542523230
-
Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126
-
Evelhoch JL, LoRusso PM, He Z, DelProposto Z, Polin L, Corbett TH, Langmuir P, Wheeler C, Stone A, Leadbetter J, Ryan AJ, Blakey DC and Waterton JC: Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126. Clin Cancer Res 10: 3650-3657, 2004.
-
(2004)
Clin Cancer Res
, vol.10
, pp. 3650-3657
-
-
Evelhoch, J.L.1
LoRusso, P.M.2
He, Z.3
DelProposto, Z.4
Polin, L.5
Corbett, T.H.6
Langmuir, P.7
Wheeler, C.8
Stone, A.9
Leadbetter, J.10
Ryan, A.J.11
Blakey, D.C.12
Waterton, J.C.13
-
17
-
-
33645732100
-
Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors
-
Beerepoot LV, Radema SA, Witteveen EO, Thomas T, Wheeler C, Kempin S and Voest EE: Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors. J Clin Oncol 24: 1491-1498, 2006.
-
(2006)
J Clin Oncol
, vol.24
, pp. 1491-1498
-
-
Beerepoot, L.V.1
Radema, S.A.2
Witteveen, E.O.3
Thomas, T.4
Wheeler, C.5
Kempin, S.6
Voest, E.E.7
-
18
-
-
40549125995
-
Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors
-
LoRusso PM, Gadgeel SM, Wozniak A, Barge AJ, Jones HK, DelProposto ZS, DeLuca PA, Evelhoch JL, Boerner SA and Wheeler C: Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors. Invest New Drugs 26: 159-167, 2008.
-
(2008)
Invest New Drugs
, vol.26
, pp. 159-167
-
-
LoRusso, P.M.1
Gadgeel, S.M.2
Wozniak, A.3
Barge, A.J.4
Jones, H.K.5
DelProposto, Z.S.6
DeLuca, P.A.7
Evelhoch, J.L.8
Boerner, S.A.9
Wheeler, C.10
-
19
-
-
33751078812
-
The use of vascular biomarkers and imaging studies in the early clinical development of anti-tumor agents targeting angiogenesis
-
Drevs J and Schneider V: The use of vascular biomarkers and imaging studies in the early clinical development of anti-tumor agents targeting angiogenesis. J Intern Med 260: 517-529, 2006.
-
(2006)
J Intern Med
, vol.260
, pp. 517-529
-
-
Drevs, J.1
Schneider, V.2
-
20
-
-
34547681379
-
Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors
-
Drevs J, Siegert P, Medinger M, Mross K, Strecker R, Zirrgiebel U, Harder J, Blum H, Robertson J, Jürgensmeier JM, Puchalski TA, Young H, Saunders O and Unger C: Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J Clin Oncol 25: 3045-3054, 2007.
-
(2007)
J Clin Oncol
, vol.25
, pp. 3045-3054
-
-
Drevs, J.1
Siegert, P.2
Medinger, M.3
Mross, K.4
Strecker, R.5
Zirrgiebel, U.6
Harder, J.7
Blum, H.8
Robertson, J.9
Jürgensmeier, J.M.10
Puchalski, T.A.11
Young, H.12
Saunders, O.13
Unger, C.14
-
21
-
-
77955072956
-
A phase IA, open-label, dose-escalating study of PTK787/ZK 222584 administered orally on a continuous dosing schedule in patients with advanced cancer
-
Drevs J, Medinger M, Mross K, Fuxius S, Hennig J, Buechert M, Thomas A, Unger C, Chen BL, Lebwohl D and Laurent D: A phase IA, open-label, dose-escalating study of PTK787/ZK 222584 administered orally on a continuous dosing schedule in patients with advanced cancer. Anticancer Res 30: 2335-2339, 2010.
-
(2010)
Anticancer Res
, vol.30
, pp. 2335-2339
-
-
Drevs, J.1
Medinger, M.2
Mross, K.3
Fuxius, S.4
Hennig, J.5
Buechert, M.6
Thomas, A.7
Unger, C.8
Chen, B.L.9
Lebwohl, D.10
Laurent, D.11
-
23
-
-
0037112419
-
High-frequency Doppler ultrasound monitors the effects of antivascular therapy on tumor blood flow
-
Goertz DE, Yu JL, Kerbel RS, Burns PN and Foster FS: High-frequency Doppler ultrasound monitors the effects of antivascular therapy on tumor blood flow. Cancer Res 62: 6371-6375, 2002.
-
(2002)
Cancer Res
, vol.62
, pp. 6371-6375
-
-
Goertz, D.E.1
Yu, J.L.2
Kerbel, R.S.3
Burns, P.N.4
Foster, F.S.5
-
24
-
-
0037699955
-
Angiogenesis in health and disease
-
Carmeliet P: Angiogenesis in health and disease. Nat Med 9: 653-660, 2003.
-
(2003)
Nat Med
, vol.9
, pp. 653-660
-
-
Carmeliet, P.1
-
25
-
-
0036644835
-
Activity of a new vascular targeting agent, ZD6126, in pulmonary metastases by human lungadenocarcinoma in nude mice
-
Goto H, Yano S, Zhang H, Matsumori Y, Ogawa H, Blakey DC and Sone S: Activity of a new vascular targeting agent, ZD6126, in pulmonary metastases by human lungadenocarcinoma in nude mice. Cancer Res 62: 3711-3715, 2002.
-
(2002)
Cancer Res
, vol.62
, pp. 3711-3715
-
-
Goto, H.1
Yano, S.2
Zhang, H.3
Matsumori, Y.4
Ogawa, H.5
Blakey, D.C.6
Sone, S.7
-
26
-
-
0142155561
-
Vascular targeting effects of ZD6126 in a C3H mouse mammary carcinoma and the enhancement of radiation response
-
Horsman MR and Murata R: Vascular targeting effects of ZD6126 in a C3H mouse mammary carcinoma and the enhancement of radiation response. Int J Radiat Oncol Biol Phys 57: 1047-1055, 2003.
-
(2003)
Int J Radiat Oncol Biol Phys
, vol.57
, pp. 1047-1055
-
-
Horsman, M.R.1
Murata, R.2
-
27
-
-
33644876060
-
Vascular targeting in pancreatic cancer: The novel tubulin-binding agent ZD6126 reveals antitumor activity in primary and metastatic tumor models
-
Kleespies A, Köhl G, Friedrich M, Ryan AJ, Barge A, Jauch KW and Bruns CJ: Vascular targeting in pancreatic cancer: the novel tubulin-binding agent ZD6126 reveals antitumor activity in primary and metastatic tumor models. Neoplasia 7: 957-966, 2005.
-
(2005)
Neoplasia
, vol.7
, pp. 957-966
-
-
Kleespies, A.1
Köhl, G.2
Friedrich, M.3
Ryan, A.J.4
Barge, A.5
Jauch, K.W.6
Bruns, C.J.7
-
28
-
-
0035906856
-
3D microvascular architecture of pre-cancerous lesions and invasive carcinomas of the colon
-
Konerding MA, Fait E and Gaumann A: 3D microvascular architecture of pre-cancerous lesions and invasive carcinomas of the colon. Br J Cancer 84: 1354-1362, 2001.
-
(2001)
Br J Cancer
, vol.84
, pp. 1354-1362
-
-
Konerding, M.A.1
Fait, E.2
Gaumann, A.3
-
29
-
-
0032952966
-
Evidence for characteristic vascular patterns in solid tumors: Quantitative studies using corrosion casts
-
Konerding MA, Malkusch W, Klapthor B, et al: Evidence for characteristic vascular patterns in solid tumors: quantitative studies using corrosion casts. Br J Cancer 80: 724-732, 1999.
-
(1999)
Br J Cancer
, vol.80
, pp. 724-732
-
-
Konerding, M.A.1
Malkusch, W.2
Klapthor, B.3
|